【摘要】：研究背景及目的乳腺癌(Breast cancer)是世界上最常見的惡性腫瘤之一。目前我國(guó)雖然是乳腺癌發(fā)病率較低的國(guó)家,但隨著我國(guó)不斷發(fā)展的經(jīng)濟(jì)水平以及人們生活方式的改變、環(huán)境的變化等,乳腺癌發(fā)病歷程迅速增長(zhǎng)。且我國(guó)人口基數(shù)比較大,發(fā)病高峰年齡較歐美國(guó)家偏低。這些因素促使我國(guó)乳腺癌發(fā)病人數(shù)迅猛增加,嚴(yán)重威脅著婦女的健康和生命。經(jīng)過(guò)多年的研究,人們發(fā)現(xiàn),雌激素受體(ER)在乳腺癌中的表達(dá)與乳腺癌發(fā)生、預(yù)后有一定的相關(guān)性。孕激素受體(PR)是雌激素與雄激素(AR)受體結(jié)合誘導(dǎo)的產(chǎn)物。PR可抑制乳腺癌細(xì)胞株的生長(zhǎng),亦可抑制腫瘤細(xì)胞的生長(zhǎng)、轉(zhuǎn)移。乳腺癌患者中若PR陽(yáng)性,則此患者內(nèi)分泌治療效果比較好,預(yù)后也相較好。C-erbB-2是目前人們研究的一個(gè)熱點(diǎn),隨著分子生物學(xué)研究的深入,人們也不斷探索C-erbB-2在乳腺癌發(fā)生過(guò)程中所起到的作用,從而不斷完善其對(duì)相關(guān)臨床檢查和治療方法,明確C-erbB-2基因的狀況對(duì)評(píng)估乳腺癌患者預(yù)后十分重要,并有利于指導(dǎo)患者對(duì)C-erbB-2檢測(cè)陽(yáng)性的病人進(jìn)行Herceptin(赫賽汀)治療。Ki-67陽(yáng)性指數(shù)是評(píng)估腫瘤細(xì)胞增值活性的重要指標(biāo)。近年來(lái),乳腺癌中Ki-67陽(yáng)性指數(shù)的許多潛在臨床價(jià)值逐漸被認(rèn)識(shí),在乳腺癌治療方案選擇和預(yù)后評(píng)估中起著越來(lái)越重要的作用。乳腺癌轉(zhuǎn)移的主要方式是腋窩淋巴結(jié)轉(zhuǎn)移,也是影響乳腺癌預(yù)后的最主要因素。P16基因(MTS1/Ink4a)作為一種多腫瘤抑制基因,當(dāng)P16發(fā)生缺失、突變、表達(dá)異常時(shí),就會(huì)引起P16蛋白合成障礙,從而引起細(xì)胞增值失控,導(dǎo)致腫瘤的發(fā)生。綜上所述,ER、PR、C-erbB-2、Ki-67、P16在乳腺癌組織中單個(gè)的過(guò)度表達(dá)均與乳腺癌的預(yù)后有關(guān),但單一檢測(cè)上述指標(biāo)有一定的局限性,因此,本實(shí)驗(yàn)檢測(cè)乳腺癌蠟塊中ER、PR、C-erbB-2、Ki-67、P16的表達(dá)水平,綜合ER、PR、C-erbB-2等的表達(dá)情況來(lái)分析P16與乳腺癌的組織學(xué)分級(jí)、病理類型,腋窩淋巴結(jié)的轉(zhuǎn)移是否有一定的相關(guān)性。主要探討P16與乳腺癌的關(guān)系及意義。材料與方法:收集乳腺癌患者切除的組織做成的蠟塊作為實(shí)驗(yàn)研究的對(duì)象,患者術(shù)前均未接受放療、化療的治療。用免疫組織化學(xué)染色的方法來(lái)檢測(cè)40例乳腺癌組織蠟塊中的ER、PR、C-erbB-2、Ki-67、P16的表達(dá)水平。結(jié)果:1):P16陽(yáng)性表達(dá)隨組織學(xué)分級(jí)升高而逐漸降低;P16陰性表達(dá)隨組織學(xué)分級(jí)升高而逐漸升高。2):P16導(dǎo)管原位癌中表達(dá)強(qiáng)度比其他組織學(xué)類型表達(dá)要強(qiáng)。3):P16與C-erbB-2之間呈負(fù)向關(guān)系4):P16與Ki-67之間無(wú)相關(guān)性,P16在三陰乳腺癌與非三陰乳腺癌中的表達(dá)無(wú)區(qū)別意義5):腋窩淋巴結(jié)轉(zhuǎn)移組P16陽(yáng)性表達(dá)率低于無(wú)腋窩淋巴結(jié)轉(zhuǎn)移組結(jié)論:P16與乳腺癌的組織學(xué)分級(jí)有關(guān),與C-erbB-2之間呈負(fù)向關(guān)系,還和淋巴結(jié)轉(zhuǎn)移有一定的關(guān)系。
[Abstract]:Background and objective (Breast cancer) is one of the most common malignant tumors in the world. Although the incidence of breast cancer in China is relatively low, the incidence of breast cancer has increased rapidly with the development of economic level, the change of people's lifestyle and the change of environment. And the population base of our country is relatively large, the peak age of incidence is lower than that of European and American countries. These factors have led to a rapid increase in breast cancer incidence in China, which is a serious threat to women's health and life. After years of research, it has been found that the expression of estrogen receptor (ER) in breast cancer is related to the occurrence and prognosis of breast cancer. Progesterone receptor (PR) is the product of estrogen binding with androgen (AR) receptor. PR can inhibit the growth of breast cancer cell line, but also inhibit the growth and metastasis of tumor cells. If PR is positive in breast cancer patients, the endocrine therapy effect is better and the prognosis is relatively good. C-erbB-2 is a hot research topic. With the development of molecular biology, People have also been exploring the role of C-erbB-2 in the process of breast cancer, so as to improve its clinical examination and treatment methods, and clarify the status of C-erbB-2 gene in the evaluation of breast cancer patients prognosis is very important. It is helpful to instruct patients to carry out Herceptin (Herceptin) therapy. Ki-67 positive index is an important index to evaluate the proliferative activity of tumor cells. In recent years, many potential clinical values of Ki-67 positive index in breast cancer have been gradually recognized, which plays an increasingly important role in breast cancer treatment options and prognosis evaluation. The main way of metastasis of breast cancer is axillary lymph node metastasis. P16 gene (MTS1/Ink4a) is the most important factor that affects the prognosis of breast cancer. This will cause P16 protein synthesis obstacles, thus causing cell proliferation out of control, leading to tumorigenesis. To sum up, the single overexpression of C-erbB-2 and Ki-67-P16 in breast cancer tissues is related to the prognosis of breast cancer, but there are some limitations in the single detection of the above indexes. Therefore, the expression level of ER,PR,C-erbB-2,Ki-67,P16 in breast cancer wax mass was detected in this experiment. To analyze the correlation between P16 and histological grade, pathological type, axillary lymph node metastasis or not. The relationship between P16 and breast cancer and its significance were discussed. Materials and methods: paraffin lumps made from resected tissues of breast cancer patients were collected as experimental subjects. The patients were not treated with radiotherapy and chemotherapy before operation. Immunohistochemical staining was used to detect the expression of ER,PR,C-erbB-2,Ki-67,P16 in paraffin masses of 40 cases of breast cancer. Results the positive expression of P16 decreased gradually with the increase of histological grade, and the negative expression of P16 increased gradually with the increase of histological grade. 2) the positive expression of P16 was stronger than that of other histological types in carcinoma in situ. 3) the negative correlation between P16 and C-erbB-2 was negative. Line 4) there was no correlation between P16 and Ki-67. 5): the positive expression rate of P16 in axillary lymph node metastasis group was lower than that in non-axillary lymph node metastasis group. There is a negative relationship between C-erbB-2 and lymph node metastasis.
【學(xué)位授予單位】：大連醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R737.9

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 陶淑玲;人類乳腺癌的遺傳學(xué)研究新進(jìn)展[J];菏澤醫(yī)專學(xué)報(bào);2000年03期

2 趙憲琪;乳腺癌細(xì)胞系的建立與應(yīng)用研究[J];實(shí)用腫瘤學(xué)雜志;2001年03期

3 郭艷麗,宋善俊;兩種不同乳腺癌細(xì)胞系組織因子表達(dá)與細(xì)胞轉(zhuǎn)移力比較研究[J];中國(guó)醫(yī)師雜志;2005年09期

4 張霖;楊毅;魏熙胤;史玉榮;王瑞;劉洪隱;姚智;牛瑞芳;;熱療逆轉(zhuǎn)乳腺癌細(xì)胞系耐藥的實(shí)驗(yàn)研究[J];中華乳腺病雜志(電子版);2007年04期

5 徐兵河;;晚期乳腺癌的治療原則與策略[J];中國(guó)醫(yī)藥導(dǎo)報(bào);2010年06期

6 陳健;張旭;田茹;劉藝;董紅梅;郭瑞峰;梁化印;;性激素結(jié)合球蛋白在乳腺癌中的表達(dá)及意義[J];臨床與實(shí)驗(yàn)病理學(xué)雜志;2011年01期

7 孫士鵬;高磊;朱瑞麗;潘宗岱;劉貴建;;Abraxas c.1082G>A突變與中國(guó)散發(fā)性乳腺癌易感相關(guān)性研究[J];分子診斷與治療雜志;2012年04期

8 熊禮寬;王霞文;;除酶以外的乳腺癌的標(biāo)志物[J];國(guó)外醫(yī)學(xué).臨床生物化學(xué)與檢驗(yàn)學(xué)分冊(cè);1988年06期

9 ;乳腺癌[J];國(guó)外科技資料目錄.醫(yī)藥衛(wèi)生;1999年10期

10 朱新生,王明麗,王成友,段梅珍;乳腺癌p~(16)基因研究進(jìn)展[J];武警醫(yī)學(xué)院學(xué)報(bào);2000年01期

相關(guān)會(huì)議論文 前10條

1 桑梅香;單保恩;耿翠芝;楊瑞玲;王玲;;腫瘤抗原MAGE-A4在乳腺癌組織和細(xì)胞系中的表達(dá)及其作用研究[A];第五屆全國(guó)中醫(yī)藥免疫學(xué)術(shù)研討會(huì)——暨環(huán)境·免疫與腫瘤防治綜合交叉會(huì)議論文匯編[C];2009年

2 陸宇嘉;艾曉杰;李偉;;E2F3對(duì)兩種乳腺癌細(xì)胞系中基因表達(dá)影響的差異研究[A];全國(guó)動(dòng)物生理生化第十一次學(xué)術(shù)交流會(huì)論文摘要匯編[C];2010年

3 桑梅香;耿翠芝;單保恩;;p73α與14-3-3σ在不同乳腺癌細(xì)胞系中的表達(dá)及相互作用的研究[A];第四屆中國(guó)腫瘤學(xué)術(shù)大會(huì)暨第五屆海峽兩岸腫瘤學(xué)術(shù)會(huì)議論文集[C];2006年

4 常苗苗;王芳;歐陽(yáng)曉暉;賈永峰;杜華;師永紅;;HIF-1在乳腺癌細(xì)胞系MDA-MB-231增殖和凋亡中的作用和機(jī)制[A];第九屆全國(guó)腫瘤轉(zhuǎn)移學(xué)術(shù)大會(huì)暨2011年黑龍江省醫(yī)學(xué)會(huì)腫瘤學(xué)年會(huì)摘要集[C];2011年

5 郭寶紅;宋立兵;張玲;廖文婷;馮艷;劉萬(wàn)里;李滿枝;曾木圣;;Mel-18在乳腺癌中表達(dá)的意義[A];第四屆中國(guó)腫瘤學(xué)術(shù)大會(huì)暨第五屆海峽兩岸腫瘤學(xué)術(shù)會(huì)議論文集[C];2006年

6 呂新全;鄧青;李惠翔;;沉默β-catenin基因?qū)θ橄侔┘?xì)胞系MDA-MB-468干/祖細(xì)胞相關(guān)因子表達(dá)及細(xì)胞生長(zhǎng)的影響[A];中華醫(yī)學(xué)會(huì)病理學(xué)分會(huì)2010年學(xué)術(shù)年會(huì)日程及論文匯編[C];2010年

7 馬驥;趙慶利;劉文超;;RhoA在缺氧誘導(dǎo)的乳腺癌新生血管形成中的功能及其機(jī)制研究[A];中華醫(yī)學(xué)會(huì)腫瘤學(xué)分會(huì)第七屆全國(guó)中青年腫瘤學(xué)術(shù)會(huì)議——中華醫(yī)學(xué)會(huì)腫瘤學(xué)分會(huì)“中華腫瘤 明日之星”大型評(píng)選活動(dòng)暨中青年委員全國(guó)遴選論文匯編[C];2011年

8 嚴(yán)楓;譚旭艷;耿堯;鞠q，

本文編號(hào)：2231867